Sukhjit Starch (SUKHJITS)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 66.07% aligns management's interests with minority shareholders.
• Price-to-book of 1.05 is close to asset value, leaving limited speculative premium.
• Debt/equity of 0.74 is moderate and not indicative of financial distress.
• Quarterly revenue of ₹347 Cr shows meaningful operating scale.

Concerns

• ROE of 2.75% and latest quarterly net margin of roughly 0.9% (₹3 Cr profit on ₹347 Cr sales) show very weak capital productivity.
• Profit growth fell 70.96% and sales fell 7.53%, reflecting serious business deterioration.
• P/E of 44.42 is high because earnings have collapsed; there is no earnings-based margin of safety.
• Piotroski F-Score of 3/9 and FairStock Score of 0/100 indicate poor financial health and elevated risk.

AI Analysis

At ₹187.79, Sukhjit Starch has a market cap of ₹677 Cr, which is just 1.05 times its book value of ₹178.60. That sounds like a Graham-style asset play. But I've learned that a low price-to-book is only interesting if the business can earn a decent return on those assets. Here, ROE is 2.75% and ROCE is 9.43% — far below what I'd want for an agricultural processor with no obvious pricing power. The latest quarter tells the story: sales of ₹347 Cr but net profit of only ₹3 Cr. That's a margin near 0.9%. Profits have fallen about 71% year-on-year while sales have declined 7.5%, so this isn't just a temporary blip; the underlying economics have deteriorated. The P/E of 44.42 is almost meaningless with that kind of earnings collapse. I am being asked to pay roughly book value for a business earning almost nothing on that book. Debt/equity of 0.74 is manageable, and promoter holding at 66% is good, but management alignment cannot substitute for a poor business. The Piotroski score of 3 out of 9 and FairStock Score of 0/100 confirm weak fundamentals. There is no durable moat visible in these numbers; starch is largely a commodity, and the company appears to be a price taker. If this is a cyclical downturn, I would need to see sales and margins stabilize before entering. Paying ₹187.79 for ₹178.60 of book value is no bargain when current earning power is so low. I would stay on the sidelines and wait for tangible evidence of improvement.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer